Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) Debt to Equity (2016 - 2023)

vTv Therapeutics (VTVT) has disclosed Debt to Equity for 10 consecutive years, with -$0.05 as the latest value for Q1 2023.

  • Quarterly Debt to Equity rose 49.51% to -$0.05 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was -$0.05 through Mar 2023, up 49.51% year-over-year, with the annual reading at -$0.06 for FY2022, 50.85% up from the prior year.
  • Debt to Equity hit -$0.05 in Q1 2023 for vTv Therapeutics, up from -$0.06 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.03 in Q1 2019 to a low of -$0.13 in Q4 2021.
  • Historically, Debt to Equity has averaged -$0.07 across 5 years, with a median of -$0.05 in 2019.
  • Biggest YoY gain for Debt to Equity was 70.18% in 2019; the steepest drop was 1459.67% in 2019.
  • Year by year, Debt to Equity stood at -$0.05 in 2019, then skyrocketed by 32.45% to -$0.04 in 2020, then crashed by 261.5% to -$0.13 in 2021, then soared by 50.85% to -$0.06 in 2022, then increased by 24.57% to -$0.05 in 2023.
  • Business Quant data shows Debt to Equity for VTVT at -$0.05 in Q1 2023, -$0.06 in Q4 2022, and -$0.09 in Q3 2022.